<?xml version="1.0" encoding="UTF-8"?>
<p id="Par54" class="p">The present study confirmed an emerging burden of HM incidence among anaemic patients with an estimated incidence rate of 60%. This magnitude was almost eight-fold higher than the HM incidence of 8.7% reported for sub-Saharan Africa in 2008 [
 <xref ref-type="bibr" rid="CR1" class="xref">1</xref>, 
 <xref ref-type="bibr" rid="CR20" class="xref">20</xref>]. The present Congolese epidemic of HM (an incidence rate of 60% in 2016) was already close to the HM incidence rate projected to be 75% by 2030 for all of sub-Saharan Africa [
 <xref ref-type="bibr" rid="CR1" class="xref">1</xref>, 
 <xref ref-type="bibr" rid="CR7" class="xref">7</xref>]. Among the patients with incident HM (
 <italic class="italic">n</italic> = 63), this study confirmed AML and MM as the most prevalent malignancies, which is similar to previous reports from Kinshasa, DRC and other parts of Africa [
 <xref ref-type="bibr" rid="CR1" class="xref">1</xref>, 
 <xref ref-type="bibr" rid="CR6" class="xref">6</xref>, 
 <xref ref-type="bibr" rid="CR11" class="xref">11</xref>].
</p>
